<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">rpcardio</journal-id><journal-title-group><journal-title xml:lang="en">Rational Pharmacotherapy in Cardiology</journal-title><trans-title-group xml:lang="ru"><trans-title>Рациональная Фармакотерапия в Кардиологии</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1819-6446</issn><issn pub-type="epub">2225-3653</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.20996/1819-6446-2019-15-4-467-477</article-id><article-id custom-type="elpub" pub-id-type="custom">rpcardio-1997</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL STUDIES</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group></article-categories><title-group><article-title>Antihypertensive Drug Utilization in Two Districts of Northern Cyprus</article-title><trans-title-group xml:lang="ru"><trans-title>Применение антигипертензивных препаратов на примере двух областей Северного Кипра</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Тамирджи</surname><given-names>М.</given-names></name><name name-style="western" xml:lang="en"><surname>Tamirci</surname><given-names>M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Мевхибе Тамирджи – PhD (фармакология), отдел фармакологии, фармацевтический факультет</p><p>Турция, Северный Кипр, Лефке, ТР-10 Мерсин</p></bio><bio xml:lang="en"><p>Mevhibe Tamirci – PhD (pharmacology), Department of Pharmacology, Faculty of Pharmacy</p><p>Northern Cyprus, TR-10 Mersin, Turkey</p></bio><email xlink:type="simple">mtamirci@eul.edu.tr</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Демирдамар</surname><given-names>Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Demirdamar</surname><given-names>R.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Рюмейса Демирдамар – PhD (фармакология), профессор, отдел фармакологии, фармацевтический факультет</p><p>Турция, Северный Кипр, Лефке, ТР-10 Мерсин</p></bio><bio xml:lang="en"><p>Rümeysa Demirdamar ‒ PhD (pharmacology), Professor, Department of Pharmacology, Faculty of Pharmacy</p><p>Northern Cyprus, TR-10 Mersin, Turkey</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Европейский университет Лефке</institution><country>Турция</country></aff><aff xml:lang="en"><institution>European University of Lefke, Faculty of Pharmacy Lefke</institution><country>Turkey</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>01</day><month>09</month><year>2019</year></pub-date><volume>15</volume><issue>4</issue><fpage>467</fpage><lpage>477</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Tamirci M., Demirdamar R., 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Тамирджи М., Демирдамар Р.</copyright-holder><copyright-holder xml:lang="en">Tamirci M., Demirdamar R.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.rpcardio.online/jour/article/view/1997">https://www.rpcardio.online/jour/article/view/1997</self-uri><abstract><sec><title>Aim</title><p>Aim. Since the irrational use of medicine increases the risk of morbidity and mortality in hypertension, this study was aimed to evaluate antihypertensive pharmacotherapy at two districts of Northern Cyprus (NC).</p></sec><sec><title>Material and methods</title><p>Material and methods. A total of 148 prescriptions including antihypertensive drugs (n=181) were obtained by the aid of five pharmacists between November 2017 August 2018 and evaluated regarding the antihypertensive drug choices and good prescribing principles. The prescribed antihypertensive agents were classified according to the Anatomical Therapeutic Chemical Classification System (ATC) 2, 3 and 5 and the prescriptions were evaluated regarding the availability of format information.</p></sec><sec><title>Results</title><p>Results. The mean of antihypertensive agents per prescription was 1.2±0.6. According to the ATC-3 subclassification, beta-blockers (22.1%), angiotensin receptor blockers (ARBs) (22.1%), calcium channel blockers (20.4%), angiotensin converting enzyme inhibitor (ACE) inhibitors (17.7%), diuretics (13.8%) and anti-adrenergic drugs (3.9%) were prescribed. According to the ATC-5 subclassification, the most common prescribed antihypertensives were metoprolol (16.6%), amlodipine (16.0%), furosemide (8.8%), captopril (7.7%) and losartan (6.6%). There were no significant relation between the prescribed antihypertensive agents and gender and the physicians serving either in governmental or private hospitals. There were shortcomings in the prescriptions such as age, diagnosis and drug information which were crucial for the chosen of an appropriate antihypertensive agent.</p></sec><sec><title>Conclusion</title><p>Conclusion. This first pharmacoepidemiological study about antihypertensive drug utilization in NC indicates the imperfections of physicians in terms of prescribing antihypertensive agents according to the guidelines and writing a “legible and good” prescription that contains full information. These findings underline necessity of educational interventions for physicians to disseminate rational use of medicine (RUM) in the NC.</p></sec></abstract><trans-abstract xml:lang="ru"><sec><title>Цель</title><p>Цель. Поскольку нерациональное применение лекарственных средств при гипертонии приводит к росту заболеваемости и смертности, целью данного исследования является оценка антигипертензивной фармакотерапии на основе данных из двух районов Северного Кипра.</p></sec><sec><title> Материал и методы</title><p> Материал и методы. В период с ноября 2017 г. по август 2018 г. при помощи 5-ти фармацевтов было собрано 148 рецептов, содержащих назначение антигипертензивных препаратов (общее количество 181), проведена оценка рациональности выбора препаратов и надлежащего алгоритма их назначения. Назначенные антигипертензивные действующие вещества определялись по системе анатомо-терапевтическо-химической классификации (АТХ) как класс 2, 3 и 5. Рецепты оценивались с точки зрения соответствия формату.</p></sec><sec><title>Результаты</title><p>Результаты. Среднее количество антигипертензивных препаратов в рецепте составило 1,2±0,6. В рамках подкласса АТХ-3 выделялись бета-блокаторы (22,1%), блокаторы рецепторов ангиотензина (БРА) (22,1%), антагонисты кальция (20,4%), ингибиторы ангиотензинпревращающего фермента (АПФ) (17,7%), диуретики (13,8%) и анти-адренергические средства (3,9%). По подклассу АТХ-5 часто назначаемыми гипотензивными веществами являлись метопролол (16,6%), амлодипин (16,0%), фуросемид (8,8%), каптоприл (7,7%) и лозартан (6,6%). Статистически значимой корреляции типа антигипертензивного вещества и пола врача, его назначившего, а также его принадлежности государственному или частному лечебному учреждению не выявлено. В исследуемых рецептах обнаружены недочеты оформления, такие как отсутствие сведений о возрасте пациента, его диагнозе, а также указаний по применению препарата. Эта информация необходима для корректного выбора антигипертензивного препарата.</p></sec><sec><title>Заключение</title><p>Заключение. Это первое фармакоэпидемиологическое исследование применения гипотензивных препаратов на территории Северного Кипра выявило недостатки в работе врачей, назначающих антигипертензивные средства, в частности, неполное следование рекомендациям и выписка рецепта, не содержащего полную информацию. Эти результаты свидетельствуют о необходимости обучающих мероприятий для врачей для внедрения принципов рационального использования лекарственных средств в регионах Северного Кипра.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>рациональная фармакотерапия</kwd><kwd>врачи</kwd><kwd>схемы назначений</kwd><kwd>фармакоэпидемиология</kwd></kwd-group><kwd-group xml:lang="en"><kwd>rational use of medicine</kwd><kwd>physicians</kwd><kwd>prescribing patterns</kwd><kwd>pharmacoepidemiology</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Vasan R.S., Beiser A., Seshadri S., et al. Residual lifetime risk for developing hypertension in middleaged women and Men. JAMA. 2002;287:1003-10. DOI:10.1001/jama.287.8.1003.</mixed-citation><mixed-citation xml:lang="en">Vasan R.S., Beiser A., Seshadri S., et al. Residual lifetime risk for developing hypertension in middleaged women and Men. JAMA. 2002;287:1003-10. DOI:10.1001/jama.287.8.1003.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Benowitz N.L. Antihypertensive agents. In: Katzung B.G., Masters S.B., Trevor A.J., eds. Basic and Clinical Pharmacology, 12th ed. New York: McGraw Hill; 2012. pp.169-90.</mixed-citation><mixed-citation xml:lang="en">Benowitz N.L. Antihypertensive agents. In: Katzung B.G., Masters S.B., Trevor A.J., eds. Basic and Clinical Pharmacology, 12th ed. New York: McGraw Hill; 2012. pp.169-90.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Kannel W.B., Gordon T. Evaluation of cardiovascular risk in the elderly: the Framington study. Bulletin of the New York Academy of Medicine. 1978;54(6):573-91.</mixed-citation><mixed-citation xml:lang="en">Kannel W.B., Gordon T. Evaluation of cardiovascular risk in the elderly: the Framington study. Bulletin of the New York Academy of Medicine. 1978;54(6):573-91.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34(28):2159-219. DOI:10.1093/eurheartj/eht151.</mixed-citation><mixed-citation xml:lang="en">2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34(28):2159-219. DOI:10.1093/eurheartj/eht151.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Guideline for the diagnosis and management of hypertension in adults 2016. National heart foundation of Australia [cited by Jul 02, 2019]. Available from: https://www.heartfoundation.org.au/images/uploads/publications/PRO-167_Hypertension-guideline-2016_WEB.pdf.</mixed-citation><mixed-citation xml:lang="en">Guideline for the diagnosis and management of hypertension in adults 2016. National heart foundation of Australia [cited by Jul 02, 2019]. Available from: https://www.heartfoundation.org.au/images/uploads/publications/PRO-167_Hypertension-guideline-2016_WEB.pdf.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71(6):1269-324. DOI:10.1161/HYP. 0000000000000066.</mixed-citation><mixed-citation xml:lang="en">2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71(6):1269-324. DOI:10.1161/HYP. 0000000000000066.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">NICE guideline. Hypertension in adults: diagnosis and management [cited by May 28, 2019]. Available from: https://www.nice.org.uk/guidance/cg127/chapter/1-Guidance#initiating-and-monitoring-antihypertensive-drug-treatment-including-blood-pressure-targets-2.</mixed-citation><mixed-citation xml:lang="en">NICE guideline. Hypertension in adults: diagnosis and management [cited by May 28, 2019]. Available from: https://www.nice.org.uk/guidance/cg127/chapter/1-Guidance#initiating-and-monitoring-antihypertensive-drug-treatment-including-blood-pressure-targets-2.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">WHO. The rational use of drugs: report of the conference of experts. Nairobi: World Health Organization; 1985.</mixed-citation><mixed-citation xml:lang="en">WHO. The rational use of drugs: report of the conference of experts. Nairobi: World Health Organization; 1985.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Rizzo J.A., Simons W.R. Variations in compliance among hypertensive patients by drug class: implications for health care costs. Clin Ther. 1997;19(6):1446-57. DOI:10.1016/S01492918(97)80018-5.</mixed-citation><mixed-citation xml:lang="en">Rizzo J.A., Simons W.R. Variations in compliance among hypertensive patients by drug class: implications for health care costs. Clin Ther. 1997;19(6):1446-57. DOI:10.1016/S01492918(97)80018-5.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Fulhaber H.D., Luft F.C. Treatment of high blood pressurein Germany. Am J Hypertens.1998:11:7503. DOI:10.1016/s0895-7061(98)00068-5.</mixed-citation><mixed-citation xml:lang="en">Fulhaber H.D., Luft F.C. Treatment of high blood pressurein Germany. Am J Hypertens.1998:11:7503. DOI:10.1016/s0895-7061(98)00068-5.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">State Planning Organization. Population and indicators [cited by Jul 02, 2019]. Available from: http://www.devplan.org/nufus-2011/nufus%20ikinci_.pdf.</mixed-citation><mixed-citation xml:lang="en">State Planning Organization. Population and indicators [cited by Jul 02, 2019]. Available from: http://www.devplan.org/nufus-2011/nufus%20ikinci_.pdf.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Jassim Al Khaja K.A., Sequeira R.P., Mathur V.S. Rational Pharmacotherapy of hypertension in the elderly: analysis of the choice and dosage drugs. J Clin Phar Therap. 2001;26:33-42. DOI:10.1111/j.1365-2710.2001.00324.x.</mixed-citation><mixed-citation xml:lang="en">Jassim Al Khaja K.A., Sequeira R.P., Mathur V.S. Rational Pharmacotherapy of hypertension in the elderly: analysis of the choice and dosage drugs. J Clin Phar Therap. 2001;26:33-42. DOI:10.1111/j.1365-2710.2001.00324.x.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Akici A., Kalaça S., Uğurlu U., Toklu H.Z., Oktay Ş. Antihypertensive drug utilization at health centers in a district of Istanbul. Pharm World Sci. 2007;29:116-21. DOI:10.1007/s11096-007-9103-5.</mixed-citation><mixed-citation xml:lang="en">Akici A., Kalaça S., Uğurlu U., Toklu H.Z., Oktay Ş. Antihypertensive drug utilization at health centers in a district of Istanbul. Pharm World Sci. 2007;29:116-21. DOI:10.1007/s11096-007-9103-5.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Obreli Neto P.R., Nobili A., de Lyra D.P. Jr, et al. Incidence and predictors of adverse drug reactions caused by drug-drug interactions in elderly outpatients. A prospective cohort study. J Pharm Pharm Sci. 2012;15(2):332-43.</mixed-citation><mixed-citation xml:lang="en">Obreli Neto P.R., Nobili A., de Lyra D.P. Jr, et al. Incidence and predictors of adverse drug reactions caused by drug-drug interactions in elderly outpatients. A prospective cohort study. J Pharm Pharm Sci. 2012;15(2):332-43.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Bakare O.Q., Akinyinka M.R., Goodman O., et al. Antihypertensive use, prescription patterns and cost of medications in a Teaching Hospital in Lagos, Nigeria. Niger J Clin Pract. 2016;19:668-72. DOI:10.4103/1119-3077.188709.</mixed-citation><mixed-citation xml:lang="en">Bakare O.Q., Akinyinka M.R., Goodman O., et al. Antihypertensive use, prescription patterns and cost of medications in a Teaching Hospital in Lagos, Nigeria. Niger J Clin Pract. 2016;19:668-72. DOI:10.4103/1119-3077.188709.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Yürüyen G., Toprak İ.D., Toprak Z., et al. Choice of treatment based on Turkish hypertension consensus repost: Do we fellow the recommendations? Turk Kardiyol Dern Ars. 2018;46(1):25-31. DOI:10.5543/tkda.2017.86344.</mixed-citation><mixed-citation xml:lang="en">Yürüyen G., Toprak İ.D., Toprak Z., et al. Choice of treatment based on Turkish hypertension consensus repost: Do we fellow the recommendations? Turk Kardiyol Dern Ars. 2018;46(1):25-31. DOI:10.5543/tkda.2017.86344.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Sequeira R.P., Al Khaja K.A., Damanhori A.H.H., Mathur V.S. Prescribing pattern on antihypertensive drugs by family physicians and general practitioners in the primary care setting in Bahrain. J Eval Clin Pract. 2002;8(4):407-14. DOI:10.1046/j.1365-2753.2002.00370.x.</mixed-citation><mixed-citation xml:lang="en">Sequeira R.P., Al Khaja K.A., Damanhori A.H.H., Mathur V.S. Prescribing pattern on antihypertensive drugs by family physicians and general practitioners in the primary care setting in Bahrain. J Eval Clin Pract. 2002;8(4):407-14. DOI:10.1046/j.1365-2753.2002.00370.x.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Gasse C., Stieber J., Döring A., Keil U., Hense H.W. Population trends in antihypertensive drug use: results from the MONICA Augsburg Project 1984 to 1995. J Clin Epidemiol. 1999;144:726-32. DOI:10.1016/S0895-4356(99)00035-9.</mixed-citation><mixed-citation xml:lang="en">Gasse C., Stieber J., Döring A., Keil U., Hense H.W. Population trends in antihypertensive drug use: results from the MONICA Augsburg Project 1984 to 1995. J Clin Epidemiol. 1999;144:726-32. DOI:10.1016/S0895-4356(99)00035-9.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Selmanovic K., Zec S.L., Vanis N., et al. Utilisation analysis of antihypertensive drugs in Bosna and Herzegovina for the time-period 2013-2015. Mater Sociomed. 2016;28:116-20.</mixed-citation><mixed-citation xml:lang="en">Selmanovic K., Zec S.L., Vanis N., et al. Utilisation analysis of antihypertensive drugs in Bosna and Herzegovina for the time-period 2013-2015. Mater Sociomed. 2016;28:116-20.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Zanchetti A., Ruilope L.M. Antihypertensive treatment in patients with type-2 diabetes mellitus: what guidance from recent controlled randomized trials? J Hypertens. 2002;20:2099-110.</mixed-citation><mixed-citation xml:lang="en">Zanchetti A., Ruilope L.M. Antihypertensive treatment in patients with type-2 diabetes mellitus: what guidance from recent controlled randomized trials? J Hypertens. 2002;20:2099-110.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Secondary prevention of non-communicable diseases in lowand middle-income countries through community-based and health service interventions. Report of the Cambridge Meeting. World Health Organization and Wellcome Trust, 2001 [cited by Jul 02, 2019]. Available from: https://apps.who.int/iris/handle/10665/42567.</mixed-citation><mixed-citation xml:lang="en">Secondary prevention of non-communicable diseases in lowand middle-income countries through community-based and health service interventions. Report of the Cambridge Meeting. World Health Organization and Wellcome Trust, 2001 [cited by Jul 02, 2019]. Available from: https://apps.who.int/iris/handle/10665/42567.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Jamerson K., Weber M.A., Bakris G.L., et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359(23):2417-28.</mixed-citation><mixed-citation xml:lang="en">Jamerson K., Weber M.A., Bakris G.L., et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359(23):2417-28.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Dahlöf B., Sever P.S., Poulter N.R., et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366(9489):895-906. DOI:10.1016/S0140-6736(05)67185-1.</mixed-citation><mixed-citation xml:lang="en">Dahlöf B., Sever P.S., Poulter N.R., et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366(9489):895-906. DOI:10.1016/S0140-6736(05)67185-1.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Hutton B., Yazdi F., Hersi M., et al. Drug safety and effectiveness network report: A systemic review with network meta-analyses and economic evaluation comparing therapies for hypertension in nondiabetic patients. Ottawa: University of Ottowa, 2014 [cited by Jul 02, 2019]. Available from: www.ruor.uottowa.ca/handle/10393/32292.</mixed-citation><mixed-citation xml:lang="en">Hutton B., Yazdi F., Hersi M., et al. Drug safety and effectiveness network report: A systemic review with network meta-analyses and economic evaluation comparing therapies for hypertension in nondiabetic patients. Ottawa: University of Ottowa, 2014 [cited by Jul 02, 2019]. Available from: www.ruor.uottowa.ca/handle/10393/32292.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
